Published in Biomed Res Int on August 18, 2015
Loss of phosphatase and tensin homolog expression correlates with clinicopathological features of non-small cell lung cancer patients and its impact on survival: A systematic review and meta-analysis. Thorac Cancer (2017) 0.75
Clinicopathological and prognostic significance of mTOR and phosphorylated mTOR expression in patients with esophageal squamous cell carcinoma: a systematic review and meta-analysis. BMC Cancer (2016) 0.75
Prognostic Significance of Periostin and Mammalian Target of Rapamycin (mTOR) in Locally Advanced Esophageal Squamous Cell Carcinoma. Med Sci Monit (2017) 0.75
Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton. Curr Biol (2004) 16.83
The tuberous sclerosis complex. N Engl J Med (2006) 13.53
Oesophageal carcinoma. Lancet (2013) 5.48
FISH analysis of 107 prostate cancers shows that PTEN genomic deletion is associated with poor clinical outcome. Br J Cancer (2007) 2.65
PTEN: a new guardian of the genome. Oncogene (2008) 2.37
PI3K/AKT signaling pathway and cancer: an updated review. Ann Med (2014) 1.60
MicroRNAs and esophageal squamous cell carcinoma. Digestion (2010) 1.35
PTEN function: the long and the short of it. Trends Biochem Sci (2014) 1.29
Phosphorylated mTOR expression is associated with poor prognosis for patients with esophageal squamous cell carcinoma. Ann Surg Oncol (2010) 1.02
Germline PTEN mutation Cowden syndrome: an underappreciated form of hereditary kidney cancer. J Urol (2013) 0.99
PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer. Arch Gynecol Obstet (2014) 0.95
Mammalian target of rapamycin inhibition in hepatocellular carcinoma. World J Hepatol (2014) 0.94
Signalling pathways in endometrial cancer. Contemp Oncol (Pozn) (2014) 0.93
Phosphorylated p70S6K expression is an independent prognosticator for patients with esophageal squamous cell carcinoma. Surgery (2014) 0.92
[A serine/threonine kinase gene defective in Peutz-Jeghers syndrome]. Duodecim (1998) 0.89
Allosteric modulation of Ras and the PI3K/AKT/mTOR pathway: emerging therapeutic opportunities. Front Physiol (2014) 0.88
Targeted inhibition of mTOR signaling improves sensitivity of esophageal squamous cell carcinoma cells to cisplatin. J Immunol Res (2014) 0.88
Mimulone-induced autophagy through p53-mediated AMPK/mTOR pathway increases caspase-mediated apoptotic cell death in A549 human lung cancer cells. PLoS One (2014) 0.86
MGMT and PTEN as potential prognostic markers in breast cancer. Exp Mol Pathol (2011) 0.85
Inhibition of PI3K/Akt/mTOR signaling pathway enhances the sensitivity of the SKOV3/DDP ovarian cancer cell line to cisplatin in vitro. Chin J Cancer Res (2014) 0.84
The PI3K/mTOR dual inhibitor P7170 demonstrates potent activity against endocrine-sensitive and endocrine-resistant ER+ breast cancer. Breast Cancer Res Treat (2014) 0.83
[Surgical treatment of esophageal cancer : Evolution of management and prognosis over the last 3 decades]. Chirurg (2015) 0.83
Oridonin inhibits mTOR signaling and the growth of lung cancer tumors. Anticancer Drugs (2014) 0.83
Downregulation of angiogenin inhibits the growth and induces apoptosis in human bladder cancer cells through regulating AKT/mTOR signaling pathway. J Mol Histol (2015) 0.82
Combination of SF1126 and gefitinib induces apoptosis of triple-negative breast cancer cells through the PI3K/AKT-mTOR pathway. Anticancer Drugs (2015) 0.81
Targeted pathways in breast cancer: molecular and protein markers guiding therapeutic decisions. Curr Mol Pharmacol (2014) 0.79